ArticleFrontiers in neuroscience2025
Moderate pyridoxal phosphate deficiency enhances neuronal excitability and promotes calcium dysregulation.
Article in Frontiers in neuroscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Review
- Vitamin B6 in nausea and vomiting of pregnancy: metabolism, mechanisms, and clinical implications-a narrative review.Frontiers in nutrition · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Pyridoxal 5'-phosphate (PLP), the active form of pyridoxine (vitamin B6), is essential for converting glutamate into the inhibitory neurotransmitter gamma-aminobutyric acid (GABA). Severe consequences of PLP deficiency due to genetic defects are well known, but the impact of modest pyridoxine deficits remains unclear. Low pyridoxine levels have been associated with poor neurological outcomes in disease and injury, but it is uncertain whether this reflects a causal relationship or is a secondary consequence of inflammatory conditions. This study aimed to investigate the functional impact of moderate reductions in PLP activity on neuronal function. Methods: Primary mouse neuronal cultures were treated with amino-D-proline (ADP) to induce a moderate reduction in PLP activity to simulate a low pyridoxine environment. ADP concentrations were titrated to produce a small decrease in GABA expression without loss of GABAergic cells or innervation. Calcium signaling was assessed in live cells, and electrophysiological recordings were performed using multielectrode arrays to evaluate neural activity under baseline and mild pathological conditions (reduced magnesium, inflammatory environment). Results: ADP-treated neurons exhibited increased calcium signaling frequency and intensity, consistent with a hyperactive phenotype. Under mild pathological conditions, calcium signaling and accumulation were further amplified. Electrophysiological recordings revealed increased neural activity, characterized by a higher frequency of short bursts of synchronous activity and random spikes. Chronic ADP treatment led to compensatory changes in neural activity, suggesting potential differences between acute and chronic pyridoxine deficiency. Conclusion: This study demonstrates that even a modest reduction in PLP activity induces transient neuronal hyperexcitability, which may enhance the pathological effects of disease, injury, and inflammation. These findings highlight the importance of pyridoxine in maintaining neural stability and suggest that low pyridoxine levels could contribute to neurological dysfunction. Further investigation is warranted to fully understand the clinical implications of mild pyridoxine deficiency.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.